Advertisement
Screener

ACTINIUM PHARMACEUTICALS, INC. (ATNM) Increase (Decrease) in Interest Payable, Net

2.8 / 5 stars · 68/120 Roast Me

ACTINIUM PHARMACEUTICALS, INC. Increase (Decrease) in Interest Payable, Net

ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Increase (Decrease) in Interest Payable, Net of $4.04 thousand for the 12-month period ending 2012-09-30, per its 10-Q filed 2012-11-14.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2012-11-14

  • ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2012-09-30 was $119.00, a 89.02% decline year-over-year.
  • ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2012-06-30 was $1.39K.
  • ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2012-03-31 was $1.21K.
  • ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2011-12-31 was $1.32K, a 2.80% increase year-over-year.
  • ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for fiscal 2011 was $4.76K, a 26.12% decline from fiscal 2010.
  • ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for fiscal 2010 was $6.44K.
Period endIncrease (Decrease) in Interest Payable, Net 3 monthIncrease (Decrease) in Interest Payable, Net 6 monthIncrease (Decrease) in Interest Payable, Net 9 monthIncrease (Decrease) in Interest Payable, Net 12 month
2012-09-30$119.00
derived: 10-Q 12 month − 3 quarters · filed 2012-11-14
$1.50K
derived: sum of 2 quarters · filed 2012-11-14
$2.72K
derived: sum of 3 quarters · filed 2012-11-14
$4.04K
10-Q · filed 2012-11-14
2012-06-30$1.39K
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-08-29
$2.60K
10-Q/A · filed 2012-08-29
$3.92K
derived: sum of 3 quarters · filed 2012-08-29
$5.00K
derived: sum of 4 quarters · filed 2012-08-29
2012-03-31$1.21K
10-Q · filed 2012-04-23
$2.54K
derived: sum of 2 quarters · filed 2012-04-23
$3.62K
derived: sum of 3 quarters · filed 2012-04-23
2011-12-31$1.32K
10-Q · filed 2012-04-23
$2.41K
derived: sum of 2 quarters · filed 2012-04-23
$4.76K
10-K · filed 2012-04-12
2011-09-30$1.08K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14
$3.59K
10-Q · filed 2011-11-14
$3.59K
10-Q · filed 2012-11-14
2011-06-30$2.51K
10-Q/A · filed 2012-08-29
2010-12-31$1.29K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-12
$2.84K
derived: sum of 2 quarters · filed 2012-04-12
$6.44K
10-K · filed 2012-04-12
2010-09-30$1.55K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14
$5.15K
10-Q · filed 2011-11-14
2010-06-30$3.60K
10-Q · filed 2011-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
PMGC Holdings Inc. (ELAB)United States$0.037B
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
BriaCell Therapeutics Corp. (BCTX)$0.037B
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Incannex Healthcare Inc. (IXHL)$0.040B-22.32